News & Events about Reata Pharmaceuticals Inc.
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF has commenced an investigation into Reata Pharmaceuticals, Inc. (NasdaqGM: RETA). In December 2021, the U.S. Food and Drug Administration (FDA...
REATA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC Investigates the Officers and Directors of Reata Pharmaceuticals, Inc. - RETA REATA PHARMACEUTICALS INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK &...
Ticker Report
2 months ago
Shares of Reata Pharmaceuticals, Inc. (NASDAQ:RETA Get Rating) have received a consensus rating of Moderate Buy from the ten brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has given a hold ...